Literature DB >> 11989569

Evaluation of side effects of sildenafil in group of young healthy volunteers.

M Dündar1, I Koçak, S O Dündar, H Erol.   

Abstract

We evaluated the safety and side effects of sildenafil in a group of sexually active volunteers younger than 40 years under conditions without sexual stimulation. Single oral dose of 50 mg dildenafil (n = 20) or placebo (n = 20) was randomly administered to 40 sexually active volunteers with the mean age of 26.80 +/- 5.29 in sildenafil group and 25.70 +/- 4.95 in placebo group. All the subjects were informed about the study, but not about the medicine. The following tests were performed immediately before and 90 minutes after the administration of the medicine: resting heart rate, blood pressure, electrocardiogram, visual acuity, color vision. The subjects were also asked to describe any discomfort or difference. Mann Whitney U test was used for statistical analyses. The only statistically significant difference was between heart rates before and after the administration of the sildenafil (p = 0.02). Color vision, visual acuity tests yielded no differences. The decrease in blood pressure was not significant. The most common side effects were flushing (75% and 0%), headache (50% and 5%), dyspepsia (15% and 5%), unintentional incomplete sexual arousal (15% and 0%) and palpitation (15% and 10%) in groups of sildenafil and placebo, respectively. The only serious side effect requiring medical treatment was arthralgia on the knee in one subject. Although these side effects can be acceptable, the likelihood of these side effects needs to be made clear to potential users of this medication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11989569     DOI: 10.1023/a:1015056416501

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  11 in total

1.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

2.  Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group.

Authors:  H Padma-Nathan; W D Steers; P A Wicker
Journal:  Int J Clin Pract       Date:  1998-09       Impact factor: 2.503

Review 3.  Update on male erectile dysfunction.

Authors:  G Wagner; I Saenz de Tejada
Journal:  BMJ       Date:  1998-02-28

4.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.

Authors:  D K Walker; M J Ackland; G C James; G J Muirhead; D J Rance; P Wastall; P A Wright
Journal:  Xenobiotica       Date:  1999-03       Impact factor: 1.908

5.  Effects of sildenafil citrate on human hemodynamics.

Authors:  G Jackson; N Benjamin; N Jackson; M J Allen
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

6.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

Authors:  R M Wallis; J D Corbin; S H Francis; P Ellis
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

7.  Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Authors:  M Boolell; S Gepi-Attee; J C Gingell; M J Allen
Journal:  Br J Urol       Date:  1996-08

8.  Treatment of erectile dysfunction with sildenafil.

Authors:  L S Marks; C Duda; F J Dorey; M L Macairan; P B Santos
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

9.  Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

Authors:  M S Rendell; J Rajfer; P A Wicker; M D Smith
Journal:  JAMA       Date:  1999-02-03       Impact factor: 56.272

10.  Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction.

Authors:  A Morales; C Gingell; M Collins; P A Wicker; I H Osterloh
Journal:  Int J Impot Res       Date:  1998-06       Impact factor: 2.896

View more
  2 in total

1.  Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

Authors:  Zhi Shi; Amit K Tiwari; Suneet Shukla; Robert W Robey; Satyakam Singh; In-Wha Kim; Susan E Bates; Xingxiang Peng; Ioana Abraham; Suresh V Ambudkar; Tanaji T Talele; Li-Wu Fu; Zhe-Sheng Chen
Journal:  Cancer Res       Date:  2011-03-14       Impact factor: 12.701

Review 2.  Visual Side Effects Linked to Sildenafil Consumption: An Update.

Authors:  Eva Ausó; Violeta Gómez-Vicente; Gema Esquiva
Journal:  Biomedicines       Date:  2021-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.